open access

Vol 23, No 4 (2016)
INTERVENTION/VALVULAR HEART DISEASE - Original articles
Published online: 2016-06-10
Get Citation

Changes in serum biomarker profiles after percutaneous mitral valve repair with the MitraClip system

Ji-Na Yoon, Antonio H. Frangieh, Adrian Attinger-Toller, Christiane Gruner, Felix C. Tanner, Maurizio Taramasso, Roberto Corti, Thomas F. Lüscher, Frank Ruschitzka, Dominique Bettex, Francesco Maisano, Oliver Gaemperli
DOI: 10.5603/CJ.a2016.0024
·
Pubmed: 27296161
·
Cardiol J 2016;23(4):384-392.

open access

Vol 23, No 4 (2016)
INTERVENTION/VALVULAR HEART DISEASE - Original articles
Published online: 2016-06-10

Abstract

Background: Mitral regurgitation (MR) is one of the most common valvular diseases. Percu­taneous mitral valve repair with the MitraClipTM system is a novel percutaneous mitral valve repair (PMVR) technique for high-surgical-risk patients. However, the effect of PMVR on cir­culating cardiac or inflammatory biomarkers and their association with individual functional, echocardiographic and clinical outcomes is poorly investigated.

Methods: A group of 144 patients with functional or degenerative MR (age, 75 ± 11 years; 41% females) underwent PMVR with the MitraClip system at the University Heart Center Zu­rich. Serum biomarkers as N-terminal pro-B-type natriuretic peptide (NT-proBNP), C-reactive protein (CRP) and creatinine were obtained from venous sampling at baseline and follow-up of 3–6 months.

Results: Median NT-proBNP decreased insignificantly from 2,942 (IQR 1,596–5,722) to 2,739 (IQR 1,440–4,296) ng/L, p = 0.21. NT-proBNP changes did not correlate with baseline left ventricular (LV) ejection fraction or LV dimensions, with New York Heart Association class on follow-up, or with clinical events on follow-up. CRP levels reached a peak on the third postoperative day at 34.0 mg/L with a subsequent slow decrease over the ensuing days.

Conclusions: Despite successful PMVR, NT-proBNP remain fairly unchanged on follow-up and changes in NT-proBNP levels are poor predictors of functional improvement or clinical outcome after MitraClip treatment.

Abstract

Background: Mitral regurgitation (MR) is one of the most common valvular diseases. Percu­taneous mitral valve repair with the MitraClipTM system is a novel percutaneous mitral valve repair (PMVR) technique for high-surgical-risk patients. However, the effect of PMVR on cir­culating cardiac or inflammatory biomarkers and their association with individual functional, echocardiographic and clinical outcomes is poorly investigated.

Methods: A group of 144 patients with functional or degenerative MR (age, 75 ± 11 years; 41% females) underwent PMVR with the MitraClip system at the University Heart Center Zu­rich. Serum biomarkers as N-terminal pro-B-type natriuretic peptide (NT-proBNP), C-reactive protein (CRP) and creatinine were obtained from venous sampling at baseline and follow-up of 3–6 months.

Results: Median NT-proBNP decreased insignificantly from 2,942 (IQR 1,596–5,722) to 2,739 (IQR 1,440–4,296) ng/L, p = 0.21. NT-proBNP changes did not correlate with baseline left ventricular (LV) ejection fraction or LV dimensions, with New York Heart Association class on follow-up, or with clinical events on follow-up. CRP levels reached a peak on the third postoperative day at 34.0 mg/L with a subsequent slow decrease over the ensuing days.

Conclusions: Despite successful PMVR, NT-proBNP remain fairly unchanged on follow-up and changes in NT-proBNP levels are poor predictors of functional improvement or clinical outcome after MitraClip treatment.

Get Citation

Keywords

MitraClip, mitral regurgitation, percutaneous mitral valve repair, serum biomarkers, NT-proBNP

About this article
Title

Changes in serum biomarker profiles after percutaneous mitral valve repair with the MitraClip system

Journal

Cardiology Journal

Issue

Vol 23, No 4 (2016)

Pages

384-392

Published online

2016-06-10

DOI

10.5603/CJ.a2016.0024

Pubmed

27296161

Bibliographic record

Cardiol J 2016;23(4):384-392.

Keywords

MitraClip
mitral regurgitation
percutaneous mitral valve repair
serum biomarkers
NT-proBNP

Authors

Ji-Na Yoon
Antonio H. Frangieh
Adrian Attinger-Toller
Christiane Gruner
Felix C. Tanner
Maurizio Taramasso
Roberto Corti
Thomas F. Lüscher
Frank Ruschitzka
Dominique Bettex
Francesco Maisano
Oliver Gaemperli

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl